89848-54-4 Usage
Uses
Used in Pharmaceutical Industry:
2-Allyl-4-[4-(4-4-[(2R,4S)-2-(2,4-dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl-piperazin-1-yl)-phenyl]-2,4-dihydro-[1,2,4]triazol-3-one is used as a pharmaceutical agent for its potential therapeutic applications. Given its structural complexity and diversity of functional groups, it may exhibit a range of biological activities, making it a candidate for the development of new drugs targeting various diseases.
Used in Antifungal Applications:
As a compound with fungicidal activity, 2-Allyl-4-[4-(4-4-[(2R,4S)-2-(2,4-dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl-piperazin-1-yl)-phenyl]-2,4-dihydro-[1,2,4]triazol-3-one is related to Itraconazole, an orally active antimycotic. It may be utilized in the development of new antifungal medications, particularly for the treatment of fungal infections that are resistant to existing therapies.
Used in COVID-19 Research:
2-Allyl-4-[4-(4-4-[(2R,4S)-2-(2,4-dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl-piperazin-1-yl)-phenyl]-2,4-dihydro-[1,2,4]triazol-3-one is also a COVID-19-related research product. Its potential use in this context could involve the exploration of its antiviral properties or its capacity to modulate immune responses, which may contribute to the development of treatments or preventive measures against COVID-19.
Check Digit Verification of cas no
The CAS Registry Mumber 89848-54-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,9,8,4 and 8 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 89848-54:
(7*8)+(6*9)+(5*8)+(4*4)+(3*8)+(2*5)+(1*4)=204
204 % 10 = 4
So 89848-54-4 is a valid CAS Registry Number.
89848-54-4Relevant academic research and scientific papers
Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones
Heeres,Backx,Van Cutsem
, p. 894 - 900 (2007/10/02)
A series of novel triazol-3-ones has been synthesized, and their in vitro and in vivo antifungal properties are reported. Traconazole. which displays a pronounced oral activity against vaginal candidosis in rats and against microsporosis in guinea pigs, has been selected for clinical evaluation.
